A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Acronyms REACH2
- Sponsors Novartis
- 31 Mar 2017 According to an Incyte Corporation media release, the first patient entered in this trial.
- 10 Mar 2017 Planned primary completion date changed from 22 Oct 2018 to 30 Sep 2020.
- 14 Feb 2017 According to Incyte Corporation media release, this trial is expected to begin in 2017.